Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.41 |
| ▸ | JAK3 | P52333 | 16/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19916808 | 0.92 | JAK2 (0.42) | JAK2JAK3SMPD3PIK3CG | |
| SCHEMBL19413053 | 0.87 | JAK2 (0.42) | JAK2JAK3SMPD3PIK3CGTLR7 | |
| SCHEMBL19413023 | 0.81 | JAK2 (0.43) | JAK2JAK3SMPD3PIK3CG | |
| SCHEMBL3711979 | 0.77 | SMPD3 (0.43) | JAK2JAK3SMPD3PIK3CG | |
| SCHEMBL24408132 | 0.72 | RAB9A (0.37) | — | |
| SCHEMBL21555751 | 0.70 | JAK2 (0.41) | JAK2JAK3SMPD3PIK3CGTLR7 | |
| SCHEMBL24880503 | 0.70 | JAK2 (0.41) | JAK2JAK3SMPD3PIK3CGTLR7 | |
| SCHEMBL19916796 | 0.69 | SMPD3 (0.45) | SMPD3 | |
| SCHEMBL16646749 | 0.68 | JAK2 (0.46) | JAK2JAK3SMPD3PIK3CG | |
| SCHEMBL21555749 | 0.68 | JAK2 (0.40) | JAK2JAK3SMPD3PIK3CGTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | JAK2 51/4885JAK3 171/4885SMPD3 588/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | JAK2 51/4885JAK3 171/4885SMPD3 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.